<DOC>
	<DOCNO>NCT00324727</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , work different way stop growth tumor cell , either kill cell stop divide . Giving melphalan directly arteries around tumor may kill tumor cell . It yet know whether hepatic arterial infusion melphalan effective standard therapy treat liver metastasis due melanoma . PURPOSE : This randomized phase III trial study hepatic arterial infusion melphalan see well work compare standard therapy treat patient unresectable liver metastasis due melanoma .</brief_summary>
	<brief_title>Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy Treating Patients With Unresectable Liver Metastases Due Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare hepatic progression-free survival patient unresectable liver metastasis secondary ocular cutaneous melanoma treat percutaneous isolated hepatic arterial perfusion ( PHP ) melphalan subsequent venous hemofiltration v best alternative standard treatment . Secondary - Determine response rate duration response patient treat melphalan PHP . - Determine pattern recurrence patient treat melphalan PHP . - Compare overall survival patient treat regimen . - Compare safety tolerability regimens patient . - Determine pharmacokinetics melphalan PHP . OUTLINE : This multicenter study . Patients stratify accord site disease ( ocular vs cutaneous ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo isolate hepatic arterial infusion melphalan 30 minute day 1 . Treatment repeat every 4 week 4 course absence disease progression unacceptable toxicity . Patients complete partial response undergo 2 additional course absence ongoing increase toxicity . - Arm II : Patients receive best alternative therapy comprise supportive care , systemic regional chemotherapy , hepatic artery ( chemo ) -embolization , appropriate therapy National Cancer Institute therapy discretion physician . Patients may cross arm I evidence disease progression . Blood sample collect periodically pharmacokinetic analysis melphalan . After completion study treatment , patient follow periodically 4 year annually survival . PROJECTED ACCRUAL : A total 92 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm liver metastasis secondary cutaneous ocular melanoma Unresectable disease Predominantly parenchyma liver Measurable disease CT scan and/or MRI Limited unresectable extrahepatic disease allow provided lifelimiting component progressive disease liver , include , limited , follow : Up 4 pulmonary nodule , &lt; 1 cm diameter Retroperitoneal lymph node &lt; 3 cm diameter Less 10 skin subcutaneous metastasis &lt; 1 cm diameter Asymptomatic bone metastasis eligible undergone palliative externalbeam radiotherapy Solitary metastasis site resect PATIENT CHARACTERISTICS : Life expectancy ≥ 3 month ECOG performance status 02 Bilirubin &lt; 3.0 mg/dL PT within 2 second upper limit normal ( ULN ) AST/ALT ≤ 10 time ULN Platelet count &gt; 75,000/mm^3 Hematocrit &gt; 27 % ( may achieve transfusion ) Absolute neutrophil count ≥ 1,300/mm^3 Creatinine ≤ 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min Fertile patient must use effective contraception Not pregnant nursing Negative pregnancy test No history congestive heart failure LVEF ≥ 40 % No significant chronic obstructive pulmonary disease ( COPD ) chronic pulmonary restrictive disease FEV_1 ≥ 30 % DLCO ≥ 40 % predict Weight ≥ 35 kg No untreated active bacterial infection systemic manifestation ( e.g. , malaise , fever , leucocytosis ) No severe allergic reaction iodine contrast unless reaction control antihistamine and/or steroid No know hypersensitivity melphalan No positive serology HIV , hepatitis B surface antigen , hepatitis C antibody ( pharmacokinetics portion study ) No know latex allergy No Childs B C cirrhosis No evidence portal hypertension history , endoscopy , radiological study No prior history gastrinoma PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 1 month since prior chemotherapy , radiotherapy , biologic therapy cancer recover No prior regionally deliver melphalan No prior Whipple procedure No concurrent immunosuppressive therapy No concurrent chronic anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>metastatic intraocular melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
</DOC>